GILD stock sentiment todayGilead Sciences, Inc.

Gilead is undergoing a powerful re-rating as it successfully transitions from a legacy HIV/HCV player into a high-growth oncology and liver disease powerhouse.

Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for GILD. Not financial advice.

The narrative has shifted from 'stagnant value trap' to 'growth breakout.' Recent headlines highlight decade-high sales growth and significant valuation discounts despite hitting record highs. While insider selling by the CEO under a preset plan is noted, the market is focused on upward price target revisions and the potential for long-term sustainability through 2027.

• ·Record-breaking sales growth in Q3
• ·Lenacapavir's massive potential in HIV PrEP
• ·Oncology portfolio scaling (Trodelvy)
• ·Analyst upward revisions and 'deep value' narrative

Gilead maintains a robust balance sheet with significant free cash flow generation that supports a reliable dividend (currently ~3.6% yield). While debt levels increased following acquisitions, the rapid growth in the oncology segment and the resilience of the Biktarvy franchise provide high-margin stability.

• ·Forward P/E around 12-14x (historically low vs. S&P 500)
• ·Strong Free Cash Flow yield
• ·Double-digit non-HIV revenue growth
• ·Operating margins consistently above 35%

Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.

Mixed conviction — no decisive signal from insiders or the holder base.

• ·No open-market insider trades in the last 120 days.

Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.

• ·Patent expiration for key HIV drugs later this decade
• ·Regulatory hurdles for new drug indications
• ·High competition in the oncology space from big pharma peers
• ·Integration risks from recent M&A activity

How direct competitors stack up against GILD right now.

• NEUTRAL
  GSKGSK plc

  COLDER — faces ongoing Zantac litigation overhangs and slower growth in its core respiratory portfolio compared to Gilead's oncology pivot.

  See full analysis →
• HOT
  ABBVAbbVie Inc.

  NEUTRAL — while showing similar strength in immunology, Gilead offers a more attractive entry valuation relative to its recent growth acceleration.

  See full analysis →
• HOT
  VRTXVertex Pharmaceuticals

  HOTTER — commands a premium valuation due to a monopoly in cystic fibrosis and higher projected EPS growth, though lacks Gilead's dividend yield.

  See full analysis →

Consensus average of 23 analysts · median 175.00

Source: StockAnalysis.com · updated 2026-11-02

• Yahoo Finance
  Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target Increases
• Investor's Business Daily
  How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade
• Trefis
  What Is Behind The Move In Kinross Gold Stock?
• The Motley Fool
  Not Newmont. Not Barrick. This Gold Stock Collects Cash Without Running a Mine.
• Simply Wall St
  Gilead (GILD) Stock May Trade At A 47% Discount Following Raised Guidance
• Seeking Alpha
  Gilead Sciences: Why I Remain Bullish After Q3